Clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and cardiopulmonary diseases
Clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and cardiopulmonary diseases. Its lead candidate, ORJ-001, is a subcutaneous peptide β1 integrin agonist designed to restore alveolar epithelial type 2 cell function, promote lung repair, and reduce inflammatory and fibrotic signaling in idiopathic pulmonary fibrosis.